Lung cancer diagnostics firm Biodesix has introduced Nodify CDT, a blood-based test kit designed to help identify patients with lung nodules that are at high risk of being malignant.
The test detects circulating antibody proteins generated by the patient's immune system in the presence of lung cancer, according to Biodesix. The firm said its lab in De Soto, KS, can typically provide results within a day of receiving a blood sample.
Nodify CDT will complement the company's current Nodify XL2 test kit, which is designed to help identify patients with lung nodules at low risk of malignancy. Biodesix will offer both products together, enabling physicians to order the tests from a single blood draw.